Bank of New York Mellon’s AbCellera Biologics ABCL Stock Holding History

Bank of New York Mellon’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-787,979	Closed	-$5.94M	–	4378
2023 Q1	$5.94M	Sell	787,979 -7,106	-0.9%	-$64.5K	﹤0.01%	2202
2022 Q4	$8.05M	Buy	795,085 +23,841	+3%	+$275K	﹤0.01%	2044
2022 Q3	$7.63M	Buy	771,244 +81,706	+12%	+$896K	﹤0.01%	2064
2022 Q2	$7.34M	Buy	+689,538	New	+$5.84M	﹤0.01%	2112
2021 Q4	–	Sell	-28,613	Closed	-$573K	–	4616
2021 Q3	$573K	Sell	28,613 -60,358	-68%	-$1.07M	﹤0.01%	3732
2021 Q2	$1.96M	Buy	+88,971	New	+$2.45M	﹤0.01%	2991

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bank of New York Mellon's ABCL Position: Q2 2023 in Review

Bank of New York Mellon sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 787,979 shares — an estimated $5.94M sold.

Bank of New York Mellon first reported a position in ABCL in Q2 2021 and held it in 6 quarters. The position peaked at $8.05M in Q4 2022. 170 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

Bank of New York Mellon reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
Bank of New York Mellon sold 787,979 AbCellera Biologics shares in Q2 2023, an estimated $5.94M.
Bank of New York Mellon first reported a position in AbCellera Biologics in Q2 2021 and held it in 6 quarters.
Bank of New York Mellon's AbCellera Biologics position peaked at $8.05M in Q4 2022.
170 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Bank of New York Mellon's 13F filing for Q2 2023, filed 3 Aug 2023.